Imaging Patients With Kidney Disease: How Do We Approach Contrast-Related Toxicity?
暂无分享,去创建一个
[1] Michael Weber,et al. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. , 2010, European journal of radiology.
[2] P. Kalra,et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[3] Diego R. Martín,et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast‐enhanced MRI protocols , 2010, Journal of magnetic resonance imaging : JMRI.
[4] B. Taouli,et al. Diffusion-weighted MR imaging of the liver. , 2010, Radiology.
[5] J. Kline,et al. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[6] Diego R. Martín,et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. , 2009, Radiology.
[7] Peter Caravan,et al. Primer on gadolinium chemistry , 2009, Journal of magnetic resonance imaging : JMRI.
[8] M. Prince,et al. Renal artery stenosis: imaging options, pitfalls, and concerns. , 2009, Progress in cardiovascular diseases.
[9] S. Sauk,et al. Ten-Year Experience With Nephrogenic Systemic Fibrosis: Case-Control Analysis of Risk Factors , 2009, Journal of computer assisted tomography.
[10] H. Thomsen,et al. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function? , 2009, Acta radiologica.
[11] M. Perazella. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm , 2009, Current opinion in nephrology and hypertension.
[12] M. Prince,et al. Nephrogenic systemic fibrosis and its impact on abdominal imaging. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.
[13] Stephanie R Wilson,et al. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? , 2009, AJR. American journal of roentgenology.
[14] Marino Labinaz,et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[15] Perazella Ma. Radiocontrast-induced nephropathy: an update. , 2009 .
[16] Paula M Jacobs,et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? , 2009, Kidney international.
[17] S. Lai,et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. , 2009, Radiology.
[18] G. Wilson,et al. Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. , 2009, Magnetic resonance imaging clinics of North America.
[19] M. Perazella,et al. Current status of gadolinium toxicity in patients with kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[20] Harold I Feldman,et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] M. Perazella. Radiocontrast-induced nephropathy: an update. , 2009, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[22] M. Perazella,et al. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] Martin R Prince,et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.
[24] M. Fine,et al. Incidence and outcomes of contrast-induced AKI following computed tomography. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[25] M. Mack,et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[26] P. Patel,et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] D. Broome,et al. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. , 2008, European journal of radiology.
[28] M. Perazella,et al. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[29] R. Reilly. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[30] H. Hussain,et al. Nephrogenic systemic fibrosis: a report of 29 cases. , 2008, AJR. American journal of roentgenology.
[31] J. Topf,et al. Nephrogenic Fibrosing Dermopathy , 2008, TheScientificWorldJournal.
[32] H. Thomsen,et al. High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.
[33] S. Punwani,et al. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Non‐Gadolinium Options for the Imaging of CKD/ESRD Patients , 2008, Seminars in dialysis.
[34] R. Woolson,et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[35] D. Tudorascu,et al. Nephrogenic systemic fibrosis: Center case review , 2007, Journal of magnetic resonance imaging : JMRI.
[36] L. Skov,et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] A. Jardine,et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. , 2007, Radiology.
[38] W. Eubank,et al. Steady‐state free precession MRA of the renal arteries: Breath‐hold and navigator‐gated techniques vs. CE‐MRA , 2007, Journal of magnetic resonance imaging : JMRI.
[39] G. Scott,et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. , 2007, Journal of the American Academy of Dermatology.
[40] A. Djamali,et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.
[41] S. Cowper,et al. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[42] Gerald A Kirk,et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.
[43] V. Runge,et al. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.
[44] J. Zic,et al. Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.
[45] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[46] D. Elston. Community-acquired methicillin-resistant Staphylococcus aureus. , 2007, Journal of the American Academy of Dermatology.
[47] S. Cowper,et al. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[48] R. Bucala,et al. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) , 2006, Current opinion in rheumatology.
[49] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[50] B. Krumme,et al. Renal Doppler Sonography – Update in Clinical Nephrology , 2006, Nephron Clinical Practice.
[51] Kirk N. Garratt,et al. Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention , 2002, Circulation.
[52] G. Dangas,et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. , 2000, Journal of the American College of Cardiology.
[53] P. Leboit,et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.
[54] H. Thomsen,et al. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.
[55] W. O’Neill,et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.
[56] C. Viscoli,et al. The effect of acute renal failure on mortality. A cohort analysis. , 1996, JAMA.